HIV Prevention Trials Network

Clarification Memorandum # 03 to:

HPTN 059, Phase II Expanded Safety and Acceptability Study of the Vaginal Microbicide 1% Tenofovir Gel, Version# 2.0, Dated 13 March 2006

IND #55, 690

Date of Clarification Memorandum: 16 May 2007

Section 1: Deletion from the HPTN059 Protocol Team Roster

Protocol Team Roster (Page vi) to be updated to delete:

Robin Fisher, RN, MSA
HPTN CORE Sr. Clinical Research Manager
Family Health International
2224 E NC Hwy 54
Durham, NC 27713
Phone: 919.544.7040, ext 458
Fax: 919.544.0207
E-mail: rfisher@fhi.org

Marion L. Williams, PhD
Assistant Professor
Clinical Pharmacology
Johns Hopkins University
600 N. Wolfe St., 501 Osler
Baltimore, MD 21287
Phone: 410.502.3252
Fax: 410.614.9978
Email: mwilli85@jhmi.edu

Craig W. Hendrix, M.D.
Associate Professor of Medicine
Johns Hopkins University School of Medicine
600 N. Wolfe St.
Baltimore, MD 21287
Phone: 410-955-9707
Fax: 410-955-9708
Email: cwhendrix@jhmi.edu
Section 2: Summary of Clarifications and Rationale

The procedures clarified in this memorandum have been approved by the NIAID Medical Officer and are to be implemented immediately upon issuance. IRB approval of this Clarification Memorandum is not required by the sponsor; however, investigators may submit the clarification memo to the IRBs/ECs overseeing the study at their site for their information.

This clarification memo is official HPTN 059 protocol documentation. It is effective immediately. A copy of this memo must be retained in each study site’s Essential Documents file for HPTN 059.

No change in the informed consent form are necessitated by or included in this Clarification Memo.

The primary goal for this clarification memo is:
To develop the following operational guidance to eliminate inconsistency and reduce any ambiguity in the interpretation and application of instructions for PK level collection across study sites.

Section 3: Implementation

Text to be deleted is noted below by strikethrough; text to be added is noted below in bold.

1. Section 1.3.5 (Page 8 of 65), first paragraph, third sentence will be changed to:
   In order to obtain an assay, for one blood will be collected approximately two to six hours post-dose from each participant, participants in the daily dosing arm will be asked to insert their daily study gel dose the morning of the visit...

2. Section 2.4.1 (Page 13 of 65), fourth paragraph, will be changed to:
   Additionally at the Week 20 Visit participants in the daily use arm will be asked to insert their daily dose of study gel at least approximately two to six hours prior to their visit, and participants in the coitally dependant arm will be asked to insert one dose of study gel at least approximately two to six hours prior to the visit. A blood draw will be taken for PK testing approximately two to six hours post-dosing.